The agreement follows Agilent’s acquisition of Canada-based CDMO BIOVECTRA in July 2024.
EquipNet, a leading provider of surplus asset management solutions based in Canton, Mass., has announced in a press release that it has entered a reseller agreement with California-based Agilent Technologies to support the sale of select certified, pre-owned instruments (1).
An initial listing of 14 instruments—including mass spectrometers compatible with either liquid or gas chromatography, high performance or ultrahigh-pressure liquid chromatography stacks, and UV-visible spectrophotometers—was made available on EquipNet’s website via this link, with price tags ranging from $14,000 to $85,000 (2).
All of the pre-owned equipment is backed with original equipment manufacturer (OEM) warranties, according to EquipNet (1). The listing page promises a one-year manufacturer's warranty with “brand-new software, expert installation, and direct ship from the OEM” (2).
EquipNet said that Agilent’s hardware portfolio is deployed in a variety of applications, including environmental testing, life sciences, and pharmaceuticals, and that collectively, Agilent equipment is known for its analytical capabilities and capacity for high-performance testing.
“Agilent is globally recognized for its innovation, precision, and reliability in the lab instrumentation space,” the press release stated (1).
“Collaborating with Agilent allows us to deliver the best of both worlds—affordable, pre-owned laboratory equipment, coupled with the assurance of an OEM warranty,” said Greg Feinberg, managing director of biotech business development at EquipNet, in the press release (1). “This reseller agreement demonstrates our commitment to enhancing the buyer’s experience and expanding our offerings to meet the growing demands of the scientific and industrial markets.”
Further expanding on the customer perspective, the press release said that offering the OEM-backed pre-owned instruments would allow buyers to be confident the items they are purchasing have the same reliability as brand-new products (1). EquipNet said the agreement underscores the company’s objective to provide customers with cost-effective solutions with an additional focus on sustainability due to the resale of surplus assets.
For Agilent, the agreement with EquipNet follows several months after a $925 million acquisition of BIOVECTRA, a contract development and manufacturing organization (CDMO) based in Canada, which was announced by Agilent on July 22, 2024 (3). In a press release, Agilent said it stood to benefit from that transaction by being able to build upon its offerings in three key areas: expansion of the company’s portfolio of services through adding sterile fill/finish services, plasmid DNA and messenger RNA capabilities, and lipid nanoparticle formulation services; growth in modalities including antibody-drug conjugates, highly potent APIs, and glucagon-like peptide-1 segments; and capabilities to support customer’s gene-editing needs as a single-source provider.
Meanwhile, EquipNet has been marking its 25th anniversary in 2024, a marker that the company recognized in a May 2024 press release.
“Reaching this 25-year milestone is a testament to our team’s dedication, innovation, and hard work,” said Roger Gallo, CEO of EquipNet, in that release (4).
1. EquipNet. EquipNet Announces Collaboration with Agilent to Offer Select Certified Pre-Owned Instruments. Press Release. Oct. 22, 2024.
2. EquipNet. Certified Pre-Owned Analytical Instruments from Agilent Technologies. equipnet.com/projects (accessed Oct. 23, 2024).
3. Agilent Technologies. Agilent to Acquire North American CDMO BIOVECTRA. Press Release, July 22, 2024.
4. EquipNet. EquipNet Celebrates 25 Years in Business. Press Release. May 2024.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.